New pill shows promise for Hard-to-Treat neuroendocrine tumors
NCT ID NCT03600233
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing an oral drug called CVM-1118 in 34 people with advanced neuroendocrine tumors that have not responded to standard treatments. The drug aims to slow tumor growth and improve disease control. Participants take the pill twice daily, with a possible dose increase if tolerated.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CVM-1118 (also called TRX-818), an oral anti-cancer drug
What this could lead to
If successful, this could provide a new treatment option for people with advanced neuroendocrine tumors that have stopped responding to standard therapies.
What could go wrong
This is a small, early-phase trial with only 34 participants, so results may not apply to everyone. The drug may not shrink tumors or improve survival, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chang Gung Memorial Hospital, KaoHsiung
Kaohsiung City, Taiwan
-
Chang Gung Memorial Hospital, LinKou
Taoyuan City, Taiwan
-
China Medical University Hospital
Taichung, Taiwan
-
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan
-
National Cheng Kung University Hospital
Tainan, 704, Taiwan
-
New Taipei Municipal TuCheng Hospital
New Taipei City, Taiwan
-
Taichung Veterans General Hospital
Taichung, Taiwan
-
Taipei Veterans General Hospital
Taipei, Taiwan